Bifogade filer
20181030_ViroGates_8-2018
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Company announcement no. 8-2018
Birkerød, 30 October 2018
ViroGates A/S (Nasdaq First North Denmark: VIRO), announced its financial results for the third quarter 2018 (1 July – 30 September) on 24 October 2018. Certain disclosed key performance indicators were wrongly stated on page 10 in the quarterly report. The following numbers have been updated in the table, which is restated in the attached PDF.
- Average number of shares before dilution and Average number of shares after dilution have been changed for the period 1 January – 30 September 2018
- Number of shares outstanding, average and Number of shares outstanding, end-period have been changed to Number of warrants outstanding, average and Number of warrants outstanding, end-period.
- Shareholders’ equity per share has been changed for all periods.
For further information contact:
CEO Jakob Knudsen
Tel. (+45) 2113 1336, Email: jk@virogates.com
ViroGates A/S
CVR-nr. 25734033, Blokken 45, DK-340 Birkerød
www.virogates.com
Certified Advisor
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se
About ViroGates
ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage and TurbiLatex test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 500 clinical trials and studies which included more than 300,000 blood samples.
Attachment